Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
WILMINGTON, Del., March 12, 2008 AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the companys investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC). T...
Advanced targeted therapies effective as first-line treatment for lung cancer
...m PT in Moscone West, Room 2001-2005, Level 2.
PLUS DOCETAXEL VERSUS DOCETAXEL AS SECOND-LINE TRE...IND PHASE III TRIAL (ZODIAC) (ABSTRACT # C2.2)
is an orally administered medication that targets ...eptors are targeted separately by other drugs, but vandetanib
is the first drug designed to target both.
AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
...dicines Agency (EMEA) for an investigational drug, vandetanib
100 mg for use in combination with chemotherapy fo...ical studies evaluating the safety and efficacy of vandetanib
100 mg in combination with chemotherapy. Pending ...l be marketed as ZACTIMA(TM).
Evaluation of vandetanib
is ongoing, as monotherapy or in combination with ...
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
...III trial has shown that the oral targeted therapy vandetanib
improves progression-free survival for patients wi...me day take a group that's receiving docetaxel and vandetanib
and see them do even better. We're not there yet, ...
In terms of side effects, patients who received vandetanib
experienced more diarrhea, rash and neutropenia. H...
Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
...day in a special platform session.
"By itself, vandetanib
inhibited tumor growth by two-thirds and decreased... the impact was even greater on tumor growth."
blocks a family of endothelial growth factors and ...tion. This trial is the first in the world to test vandetanib
Zage says in addition to the pedia...
Vandetanib Study Enters Third Phase
... 20 sites.
The patients who have a recorded a case of locally advanced or metastatic non-small cell lung cancer will be given the once-daily drug vandetanib
in addition to pemetrexed, as a second line treatment.
Says Medical Science Director for Vandetanib, Dr Peter Langmuir, 'After treatment failure w...
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
ORLANDO, Fla., May 30 Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, d...
AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
WILMINGTON, Del., Nov. 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:
AZN) announced today that it has completed enrollment of patients in the
ZEST (ZACTIMA Efficacy Study versus Tarceva) study, the first of four Phase
III trials for the investigational once-daily oral anti-cancer drug
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
- Phase III trials now underway to evaluate vandetanib
as second-line NSCLC treatment in combination with docetaxel -
WILMINGTON, Del., Sept. 20 /PRNewswire/ -- Results published today in
the Journal of Clinical Oncology(1) show that the AstraZeneca
investigational once-daily oral ...